nach oben

Erschienen in:

01.06.2019 | Case report

Bortezomib/carfilzomib/dexamethasone

Chalazia and blepharitis: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study of 16 patients receiving proteasome inhibitors at Mount Sinai Hospital in New York, USA from January 2010 to January 2017, three patients [ages and sexes not stated] were described, who developed chalazia or blepharitis following treatment with bortezomib, carfilzomib or dexamethasone for plasma cell disorders [dosages and routes not stated; not all durations of treatments to reactions onsets and outcomes not stated]. …

Sklar BA, et al. Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. BMC Ophthalmology 19: 110, No. 1, 14 May 2019. Available from: URL: http://doi.org/10.1186/s12886-019-1118-x - USA

Titel: Bortezomib/carfilzomib/dexamethasone
Chalazia and blepharitis: 3 case reports
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63949-y

Springer Medizin

Bortezomib/carfilzomib/dexamethasone

Chalazia and blepharitis: 3 case reports

Excerpt

Weitere Artikel der Ausgabe 1/2019

Immunomodulators/immunosuppressants

Prednisolone

Lenvatinib

Calcium-sulfate/tobramycin/vancomycin

Amiodarone

Sodium valproate

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Immunomodulators/immunosuppressants

Prednisolone

Lenvatinib

Calcium-sulfate/tobramycin/vancomycin

Amiodarone

Sodium valproate